Searched for
HERCEPTIN
The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garageKiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...- Biocon Biologics to introduce three new biosimilars for cancer treatmentBiocon Biologics will launch three new oncology biosimilars. These include Trastuzumab/Hyaluronidase, Nivolumab, and Pembrolizumab. The com...
- Roche launches antibody drug for breast cancer in IndiaThe drug is approved for treating both early and late stage or metastatic HER2-positive breast cancer.
- Dr Reddy's launches Hervycta to treat cancer in IndiaQuoting Ipsos data, the company said the Herceptin and its biosimilars had India sales of Rs 290 crore for the most recent 12 months ending...
- USFDA okays Mylan, Biocon's biosimilar of cancer drug HerceptinOgivri is the first USFDA approved biosimilar to Herceptin and the first biosimilar from Mylan and Biocon's joint portfolio approved in the...
- Roche, Biocon clash accusing contempt of courtRoche did not comment on the development, stating that the matter was sub judice. Biocon did not respond to ET's queries.
- Swiss drugmaker Roche launches costliest cancer drugs in IndiaKadcyla and Perjeta, the new class of drugs launched in India in October, cost Rs 2,10,000 (200 ml) and Rs 2,49,000 for a dosage, respectiv...
- Delhi HC blocks Reliance from launching copy of Roche's breast cancer drugDelhi High Court has blocked Reliance Life Sciences from launching copies of Swiss drug maker Roche’s breast cancer drug trastuzmab, brande...
- Biocon, Mylan challenge ban on using Roche dataBangalore-based Biocon and US generic drugmaker Mylan have challenged Delhi High Court’s interim order which barred them from using Roche’s...
- Health groups lash out at HC order baning Biocon, Mylan from selling biosimilar breast cancer drugPublic health groups lashed out at High Court order that stopped Biocon, Mylan from selling biosimilar versions of breast cancer drug Herce...
- Roche sues Biocon, Mylan, DCGI over breast cancer drugRoche has sued Mylan, Biocon for launching biosimilar version of the original breast cancer drug, Herceptin, and DCGI for allowing the laun...
- Mylan launches breast cancer drug in IndiaDrug major Mylan Inc today said it has launched breast cancer drug Hertraz Herceptin in India.
- Biocon launches breast-cancer drug CANMAbPriced at Rs 19,500 per vial, Biocon is expecting to target close to 35,000 patients with this drug.
- Biocon's breast cancer drug 'CANMAb' to hit markets next monthBiotechnology major Biocon will start selling breast cancer drug 'CANMAb', developed jointly with US-based Mylan, in the country from next ...
- Biocon ups generic war with nod for Roche's cancer drug cloneBiocon officials confirmed the development to ET but didn't shed light on how soon the company would be ready to bring the biosimilar to th...
- Individual cases to dictate MNC drug cos’ approach to patentsRoche’s decision to give up India patent for Herceptin unlikely to set a precedent, says MNC drug companies’ body.
- Swiss drug major Roche to drop anti-cancer drug Herceptin patent in IndiaRoche's decision is a smart move, say IP experts, as there is no Indian company manufacturing this drug due to the complex science involved.
- Roche lost Indian patent as it didn't comply local norms:GovernmentRoche lost an Indian patent for breast cancer drug 'Herceptin' as it did not comply with local norms after facing a post grant challenge, g...
- Cancer drugs made by Emcure, Roche still expensive for patientsLast year, Swiss drug maker Roche, said it had signed a deal with Emcure Pharma to manufacture low-cost versions of its breast cancer drug.
- Emcure signs deal to manufacture Roche's anti-cancer drugsSwiss drug major Roche, which is often at logger heads with Indian generic drugmakers over patent rights, has made a shift in its strategy.
Load More
